Tacabrutideg

Phase 3

MMassachusetts General Hospital

Tacabrutideg is one of 55 therapeutic programs targeting B-cell Malignancy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell MalignancyRecruiting

Chronic Lymphocytic LeukemiaRecruiting

B-Cell MalignancyPreclinical

Recruiting

Chronic Lymphocytic LeukemiaPhase 3

Recruiting

Competition

Competitive Landscape

94 competitors in Chronic Lymphocytic Leukemia

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

51 2

Gazyva

Roche

Phase 3

59 3

Fludara

Sanofi

Phase 3

38 4

Calquence

AstraZeneca

Phase 3

27 5

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

40 6

Brukinsa

BBeOne Medicines

Phase 3

17 7

Keytruda

Merck & Co.

Phase 3

2 8

Adcetris

Pfizer

Phase 3

1 9

Beqalzi

BBeOne Medicines

Phase 3

8 10

Campath

GGenzyme, a Sanofi Company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Chronic Spontaneous Urticaria

NCT07005713

Q2 2028

Phase 3Recruiting

Chronic Lymphocytic Leukemia

NCT06973187

Q4 2029

PreclinicalRecruiting

B-Cell Malignancy

NCT05006716

PreclinicalRecruiting

B-Cell Malignancy

NCT06634589

Q1 2030

Phase 3Recruiting

CLL

NCT06846671

Phase 2Recruiting

Chronic Lymphocytic Leukemia

NCT06849713

Clinical

Trials by Indication[1]

B-cell Malignancy2 trials

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

Recruiting·BBeOne Medicines·Preclinical·NCT06634589·80 enrolled

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

Recruiting·BBeOne Medicines·Preclinical·NCT05006716·645 enrolled

Chronic Lymphocytic Leukemia2 trials

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting·BBeOne Medicines·Phase 3·NCT06973187·500 enrolled

A Multicenter Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax (BOSon) or Tacabrutideg (BGB-16673), Obinutuzumab, and Sonrotoclax (DOSon) in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting·MMassachusetts General Hospital·Phase 2·NCT06849713·80 enrolled

CLL1 trial

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

Recruiting·BBeOne Medicines·Phase 3·NCT06846671·250 enrolled

Chronic Spontaneous Urticaria1 trial

A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Doses of BGB-16673 in Patients With Chronic Spontaneous Urticaria and in Healthy Participants

Recruiting· BeiGene logo

BeiGene·Phase 1·NCT07005713·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tacabrutideg. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tacabrutideg. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: MMassachusetts General Hospital

Tacabrutideg

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q4 2029

Q1 2030

Trials by Indication[1]

B-cell Malignancy2 trials

Chronic Lymphocytic Leukemia2 trials

CLL1 trial

Chronic Spontaneous Urticaria1 trial

References

Drug Info

Quick Facts

Related News